Cytheris initiates new trial in HIV patients

Published: 15-Oct-2007
Regulatory Research & Development

Cytheris to expand clinical trial programme for recombinant human Interleukin-7 - CYT107


A clinical stage biopharmaceutical company is to expand its clinical trial programme for recombinant human Interleukin-7 - CYT107 with the initiation of a PhaseI/IIa clinical trial in HIV patients.

Cytheris will conduct the trial at sites in France, Italy, Canada and the US. The trials follow the launch of previously announced PhaseI/IIa trials of IL-7 in Hepatitis C and oncology. The announcement was made at a mini symposium in Sweden last month called Frontiers in Medicine.

  • Companies:
  • Cytheris
See more

You may also like

Regulatory

Cytheris publish new oncology data

Read more
A second phase 1 trial in oncology has highlighted the potential for Interleukin-7

Trending Articles

  1. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  2. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company
  3. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  4. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
  5. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Regulatory

Cytheris publish new oncology data

A second phase 1 trial in oncology has highlighted the potential for Interleukin-7
Regulatory

Laureate in agreement to manufacture lead product candidate for Cytheris

Laureate Pharma has entered into a cGMP contract manufacturing agreement with Cytheris
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Subscribe now